Wedbush Analysts Increase Earnings Estimates for PTGX

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Analysts at Wedbush increased their Q2 2025 earnings per share estimates for Protagonist Therapeutics in a research report issued on Wednesday, May 7th. Wedbush analyst Y. Zhong now forecasts that the company will post earnings per share of ($0.59) for the quarter, up from their prior forecast of ($0.60). Wedbush currently has a "Outperform" rating and a $70.00 target price on the stock. The consensus estimate for Protagonist Therapeutics' current full-year earnings is $2.43 per share. Wedbush also issued estimates for Protagonist Therapeutics' Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.04) EPS, FY2026 earnings at ($2.75) EPS, FY2027 earnings at ($2.22) EPS and FY2028 earnings at ($0.43) EPS.

PTGX has been the subject of several other research reports. JMP Securities restated a "market outperform" rating and set a $58.00 price target on shares of Protagonist Therapeutics in a research note on Friday, February 7th. The Goldman Sachs Group decreased their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating for the company in a research report on Monday, February 24th. HC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of Protagonist Therapeutics in a research note on Thursday, April 10th. Truist Financial increased their target price on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a "buy" rating in a research report on Tuesday, March 11th. Finally, BTIG Research set a $73.00 price target on shares of Protagonist Therapeutics in a research report on Monday, March 3rd. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Protagonist Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $65.44.

Protagonist Therapeutics Stock Up 5.4%

PTGX traded up $2.30 during trading on Friday, hitting $45.27. 1,000,793 shares of the company traded hands, compared to its average volume of 872,406. Protagonist Therapeutics has a one year low of $27.00 and a one year high of $60.60. The stock's fifty day moving average is $46.95 and its 200 day moving average is $42.67. The firm has a market cap of $2.80 billion, a P/E ratio of 17.02 and a beta of 2.65.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.50) by $0.31. The firm had revenue of $28.32 million during the quarter, compared to the consensus estimate of $30.44 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%.

Insider Activity

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 30,514 shares of Protagonist Therapeutics stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the completion of the sale, the insider now directly owns 83,892 shares in the company, valued at $4,676,140.08. The trade was a 26.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director William D. Waddill sold 4,000 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $54.25, for a total transaction of $217,000.00. Following the completion of the transaction, the director now directly owns 13,130 shares of the company's stock, valued at approximately $712,302.50. This represents a 23.35% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 66,532 shares of company stock worth $3,665,786. 5.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Protagonist Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. grew its stake in shares of Protagonist Therapeutics by 127.2% in the third quarter. Franklin Resources Inc. now owns 81,591 shares of the company's stock worth $3,782,000 after purchasing an additional 45,674 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of Protagonist Therapeutics by 3,099.4% in the 3rd quarter. Principal Financial Group Inc. now owns 320,832 shares of the company's stock worth $14,437,000 after buying an additional 310,804 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Protagonist Therapeutics by 36.7% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 216,069 shares of the company's stock valued at $8,340,000 after buying an additional 58,002 shares during the period. Assenagon Asset Management S.A. bought a new position in shares of Protagonist Therapeutics during the fourth quarter valued at approximately $2,016,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Protagonist Therapeutics by 2.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 578,409 shares of the company's stock valued at $22,327,000 after acquiring an additional 12,906 shares in the last quarter. Institutional investors own 98.63% of the company's stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.